Vanta Bioscience (BOM:540729) ROCE %: 6.64% (As of Mar. 2026)


BOM:540729 Vanta Bioscience Ltd BOM:540729
56 GF Score
Price ₹25.29
GF Value ₹12.07
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Vanta Bioscience ROCE %?

Vanta Bioscience BOM:540729 +4.98% 56 ROCE % is 6.64% as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 56/100 and a GF Value™ of ₹12.07 (Significantly Overvalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vanta Bioscience's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.64%.

Vanta Bioscience  (BOM:540729) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vanta Bioscience ROCE % Related Terms

Vanta Bioscience ROCE % Historical Data

* Premium members only.

The historical data trend for Vanta Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience ROCE % Chart

Vanta Bioscience Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 -6.95 -4.79 -3.39 1.39

Vanta Bioscience Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.34 -6.51 -4.95 -3.85 6.64
BOM:540729
56GF Score
Vanta Bioscience Ltd BOM:540729
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanta Bioscience ROCE % Calculation

Vanta Bioscience's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=7.91/( ( (858.792 - 265.643) + (661.026 - 118.212) )/ 2 )
=7.91/( (593.149+542.814)/ 2 )
=7.91/567.9815
=1.39 %

Vanta Bioscience's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=32.3/( ( (568.642 - 139.128) + (661.026 - 118.212) )/ 2 )
=32.3/( ( 429.514 + 542.814 )/ 2 )
=32.3/486.164
=6.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.64% mean?
Vanta Bioscience (BOM:540729) has a ROCE % of 6.64% as of Mar. 2026.
Is Vanta Bioscience's ROCE % too high?
Vanta Bioscience's current ROCE % is 6.64%. Overall, Vanta Bioscience has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's ROCE % compare to TMO and DHR?
Vanta Bioscience's ROCE % of 6.64% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vanta Bioscience's current ROCE % is 6.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.07, compared to a current price of ₹25.29 — trading 109.5% above its estimated fair value. The current ROCE % is 6.64%. Vanta Bioscience's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current ROCE % is 6.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹25.29 is trading 109.5% above its estimated GF Value™ of ₹12.07. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • ROCE %: 6.64%
  • GF Value™: ₹12.07 vs. price of ₹25.29 (109.5% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
56GF Score

Get the complete analysis for BOM:540729

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.29
Price
₹12.07
GF Value